The estimated Net Worth of Michelle Renee Griffin is at least $939 Tisíc dollars as of 27 March 2023. Ms. Griffin owns over 2,341 units of Adaptive Biotechnologies stock worth over $90,553 and over the last 8 years she sold ADPT stock worth over $19,875. In addition, she makes $828,250 as Independent Director at Adaptive Biotechnologies.
Michelle has made over 13 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 2,341 units of ADPT stock worth $19,875 on 27 March 2023.
The largest trade she's ever made was exercising 14,916 units of Adaptive Biotechnologies stock on 27 August 2021 worth over $116,345. On average, Michelle trades about 2,428 units every 29 days since 2016. As of 27 March 2023 she still owns at least 20,627 units of Adaptive Biotechnologies stock.
You can see the complete history of Ms. Griffin stock trades at the bottom of the page.
Michelle R. Griffin serves as Independent Director of the Company. Ms. Griffin currently serves on the board of directors of Acer Therapeutics, Inc., a public company, including as chair of the audit committee. Ms. Griffin also currently serves on the board of directors of HTG Molecular Diagnostics, Inc., a public company, including as chair of the audit committee. Ms. Griffin previously served on the board of directors and as chair of the audit committee of PhaseRx, Inc., a public company, from 2016 to 2018, OncoGenex Pharmaceuticals Inc., a Nasdaq listed company, from 2008 to 2011 and Sonus Pharmaceuticals, Inc., a public company, from 2004 to 2008. Ms. Griffin served as Executive Vice President, Operations, and Chief Financial Officer at OncoGenex Pharmaceuticals, Inc. from 2011 to 2013, served as Acting Chief Executive, Senior Vice President and Chief Operating Officer at Trubion Pharmaceuticals, Inc. from 2009 until its acquisition in 2010 and as its Chief Financial Officer from 2006 to 2009; and served as Senior Vice President and Chief Financial Officer of Dendreon Corp. from 2005 to 2006. Ms. Griffin holds a BS in marketing from George Mason University and an MBA from Seattle University.
As the Independent Director of Adaptive Biotechnologies, the total compensation of Michelle Griffin at Adaptive Biotechnologies is $828,250. There are 5 executives at Adaptive Biotechnologies getting paid more, with Lance Baldo having the highest compensation of $3,707,390.
Michelle Griffin is 54, she's been the Independent Director of Adaptive Biotechnologies since 2019. There are 5 older and 16 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.
Michelle's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.
Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... a Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies executives and other stock owners filed with the SEC include: